{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:10:23Z","timestamp":1785885023576,"version":"3.56.0"},"reference-count":16,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Launched in Japan in 2022, ozoralizumab (OZR) is a novel, anti-tumour necrosis factor (TNF)-\u03b1 inhibitor for treating rheumatoid arthritis (RA) that is refractory to conventional therapies. However, there is a lack of evidence regarding its perioperative management. Methods: This retrospective case series included nine patients with RA who underwent a total of 12 either RA-related (n = 9) or unrelated (n = 3) orthopaedic procedures. We reviewed patient demographics, surgical procedures, perioperative OZR discontinuation periods, and postoperative complications. Results: The mean preoperative OZR discontinuation period was 15.8 days (range, 2\u201325 days). Sutures were removed at a mean of 12.8 days postoperatively (range, 11\u201314 days) after adequate wound healing had been confirmed. The mean total discontinuation period was 34.9 days (range, 27\u201343 days). No cases of surgical site infection (SSI) or delayed wound healing (DWH) were observed during a minimum follow-up period of three months. One patient experienced a disease flare before OZR was restarted. Conclusions: Preoperative OZR discontinuation for up to four weeks appeared to be safe in this cohort. These findings may assist orthopaedic surgeons in determining an appropriate perioperative discontinuation strategy for OZR that minimises SSI and DWH risk while reducing the likelihood of RA flare.<\/jats:p>","DOI":"10.3390\/jcm15041422","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:45:36Z","timestamp":1770831936000},"page":"1422","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative Ozoralizumab Management for Patients with Rheumatoid Arthritis Who Underwent Orthopaedic Surgery: A Retrospective Case Series"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-586X","authenticated-orcid":false,"given":"Keiichiro","family":"Nishida","sequence":"first","affiliation":[{"name":"Locomotive Pain Center, Faculty of Medical Development Field, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3673-4626","authenticated-orcid":false,"given":"Yoshihisa","family":"Nasu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Okayama City Hospital, Okayama 700-8557, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-4736","authenticated-orcid":false,"given":"Ryozo","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Kurashiki Sweet Hospital, Okayama 710-0016, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Locomotive Pain Center, Faculty of Medical Development Field, Okayama University, Okayama 700-8558, Japan"},{"name":"Department of Musculoskeletal Health Promotion, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Horita","sequence":"additional","affiliation":[{"name":"Locomotive Pain Center, Faculty of Medical Development Field, Okayama University, Okayama 700-8558, Japan"},{"name":"Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Natsumeda","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Center, Mabi Memorial Hospital, Kurashiki 710-1313, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3587-4975","authenticated-orcid":false,"given":"Shuichi","family":"Naniwa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-9307","authenticated-orcid":false,"given":"Toshifumi","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ishiwatari-Ogata, C., Kyuuma, M., Ogata, H., Yamakawa, M., Iwata, K., Ochi, M., Hori, M., Miyata, N., and Fujii, Y. (2022). Ozoralizumab, a Humanized Anti-TNFalpha NANOBODY((R)) Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFalpha IgG. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.853008"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14712598.2023.2231344","article-title":"Ozoralizumab: First Nanobody(R) therapeutic for rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18102","DOI":"10.1038\/s41598-022-23152-6","article-title":"A novel anti-TNF-alpha drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis","volume":"12","author":"Oyama","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/msc.1721","article-title":"Rheumatology patients on immunosuppressive treatment and their perioperative management: Review of recommendations","volume":"21","author":"Khader","year":"2023","journal-title":"Musculoskelet. Care"},{"key":"ref_5","first-page":"220","article-title":"Preoperative Evaluation and Management of Patients Receiving Biologic Therapies","volume":"7","author":"Rezaieyazdi","year":"2019","journal-title":"Arch. Bone Jt. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/mr\/roac019","article-title":"Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Ito","year":"2023","journal-title":"Mod. Rheumatol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/14397595.2015.1073133","article-title":"Risk factors for surgical site infection and delayed wound healing after orthopedic surgery in rheumatoid arthritis patients","volume":"26","author":"Kadota","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/14397595.2021.1913824","article-title":"Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis","volume":"32","author":"Ito","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.42140","article-title":"2022 American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty","volume":"74","author":"Goodman","year":"2022","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"ref_12","first-page":"218","article-title":"Perioperative management of disease-modifying antirheumatic drugs and other immunomodulators","volume":"1","author":"Moreira","year":"2022","journal-title":"ARP Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Terrett, A., Chin, A., Kwon, M., Whittle, S., and Hill, C. (2025). Perioperative management with DMARDs in rheumatic diseases: A scoping review of clinical guidelines. BMC Rheumatol., 9.","DOI":"10.1186\/s41927-025-00522-x"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fleury, G., Mania, S., Hannouche, D., and Gabay, C. (2017). The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Swiss Med. Wkly., 147.","DOI":"10.4414\/smw.2017.14563"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/mr\/roae089","article-title":"The use of biologic disease-modifying antirheumatic drugs does not increase surgical site infection or delayed wound healing after orthopaedic surgeries for rheumatoid arthritis","volume":"35","author":"Kiso","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFalpha NANOBODY((R)) compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials","volume":"25","author":"Takeuchi","year":"2023","journal-title":"Arthritis Res. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1422\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:01:55Z","timestamp":1770832915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041422"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041422","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}